The Forces Behind Cell Movement

Por Ananthakrishnan, Revathi, Ehrlicher, Allen
Publicado em 2007

Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials

Por Ananthakrishnan, Revathi, Green, Stephanie, Li, Daniel, LaValley, Michael
Publicado no Contemp Clin Trials Commun (2018)

2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy

Por Ananthakrishnan, Revathi, Green, Stephanie, Li, Daniel, LaValley, Michael
Publicado no Contemp Clin Trials Commun (2019)

Weak Force Stalls Protrusion at the Leading Edge of the Lamellipodium

Por Bohnet, Sophie, Ananthakrishnan, Revathi, Mogilner, Alex, Meister, Jean-Jacques, Verkhovsky, Alexander B.
Publicado em 2006

Systematic comparison of the statistical operating characteristics of various Phase I oncology designs

Por Ananthakrishnan, Revathi, Green, Stephanie, Chang, Mark, Doros, Gheorghe, Massaro, Joseph, LaValley, Michael
Publicado no Contemp Clin Trials Commun (2016)

A mitotic kinesin-6, Pav-KLP, mediates interdependent cortical reorganization and spindle dynamics in Drosophila embryos

Por Sommi, Patrizia, Ananthakrishnan, Revathi, Cheerambathur, Dhanya K., Kwon, Mijung, Morales-Mulia, Sandra, Brust-Mascher, Ingrid, Mogilner, Alex
Publicado em 2010

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma()

Por Geoerger, Birgit, Kieran, Mark W., Grupp, Stephan, Perek, Danuta, Clancy, Jill, Krygowski, Mizue, Ananthakrishnan, Revathi, Boni, Joseph P., Berkenblit, Anna, Spunt, Sheri L.
Publicado em 2011

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

Por Sangha, Randeep, Davies, Andrew, Dang, Nam H., Ogura, Michinori, MacDonald, David A., Ananthakrishnan, Revathi, Paccagnella, M. Luisa, Vandendries, Erik, Boni, Joseph, Goh, Yeow Tee
Publicado no J Drug Assess (2017)

Optical Deformability as an Inherent Cell Marker for Testing Malignant Transformation and Metastatic Competence

Por Guck, Jochen, Schinkinger, Stefan, Lincoln, Bryan, Wottawah, Falk, Ebert, Susanne, Romeyke, Maren, Lenz, Dominik, Erickson, Harold M., Ananthakrishnan, Revathi, Mitchell, Daniel, Käs, Josef, Ulvick, Sydney, Bilby, Curt
Publicado em 2005

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors

Por Spunt, Sheri L., Grupp, Stephan A., Vik, Terry A., Santana, Victor M., Greenblatt, David J., Clancy, Jill, Berkenblit, Anna, Krygowski, Mizue, Ananthakrishnan, Revathi, Boni, Joseph P., Gilbertson, Richard J.
Publicado em 2011

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Por DeAngelo, Daniel J., Stock, Wendy, Stein, Anthony S., Shustov, Andrei, Liedtke, Michaela, Schiffer, Charles A., Vandendries, Erik, Liau, Katherine, Ananthakrishnan, Revathi, Boni, Joseph, Laird, A. Douglas, Fostvedt, Luke, Kantarjian, Hagop M., Advani, Anjali S.
Publicado no Blood Adv (2017)